Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 453-462 , August 2009

The spectrum of antidiabetic actions of GLP-1 in patients with diabetes

References 

  1. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
  2. Roglic G, Unwin N, Bennett PH, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28:2130–2135
  3. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  4. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes – Results and projections from the Steno-2 study. Diabetes Care. 2008;31:1510–1515
  5. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine. 2008;359:1577–1589
  6. Chalmers J, Cooper ME. UKPDS and the legacy effect. The New England Journal of Medicine. 2008;359:1618–1620
  7. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52:17–30
  8. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of Internal Medicine. 2007;147:386–399
  9. Maedler K, Carr RD, Bosco D, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. The Journal of Clinical Endocrinology and Metabolism. 2005;90:501–506
  10. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007;87:1409–1439
  11. Holz GG. Epac: a new cAMP-binding protein in support of Glucagon-Like Peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes. 2004;53:5–13
  12. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacology and Therapeutics. 2007;113:546–593
  13. Tsuboi T, da Silva Xavier G, Holz GG, et al. Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochemical Journal. 2003;369:287–299
  14. de Heer, J. and Holst, J.J. Sulfonylurea compounds uncouple the glucose dependence of the insulinotropic effect of glucagon-like peptide 1. Diabetes 2007; 56: 438–443.
  15. Wang Y, Egan JM, Raygada M, et al. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046–38 cells. Endocrinology. 1995;136:4910–4917
  16. Kemp DM, Habener JF. Insulinotropic hormone glucagon-like peptide 1 (GLP-1) activation of insulin gene promoter inhibited by p38 mitogen-activated protein kinase. Endocrinology. 2001;142:1179–1187
  17. Lawrence MC, Bhatt HS, Easom RA. NFAT regulates insulin gene promoter activity in response to synergistic pathways induced by glucose and glucagon-like peptide-1. Diabetes. 2002;51:691–698
  18. Li Y, Cao X, Li LX, et al. Beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes. 2005;54:482–491
  19. Klinger S, Poussin C, Debril MB, et al. Increasing GLP-1-induced beta-cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes. 2008;57:584–593
  20. Buteau J, Roduit R, Susini S, et al. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. [In Process Citation] Diabetologia. 1999;42:856–864
  21. Holz GH, Kuhtreiber WM, Habener JF. Induction of glucose competence in pancreatic beta cells by glucagon- like peptide-1(7–37). Transactions of the Association of American Physicians. 1992;105:260–267
  22. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Archiv. 1998;435:583–594
  23. Flamez D, Van Breusegem A, Scrocchi LA, et al. Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes. 1998;47:646–652
  24. Bonner-Weir S. Beta-cell turnover: its assessment and implications. Diabetes. 2001;50(Suppl. 1):S20–S24
  25. Egan JM, Bulotta A, Hui H, et al. GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells. Diabetes/Metabolism Research and Reviews. 2003;19:115–123
  26. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397–4408
  27. Zhou J, Wang X, Pineyro MA, et al. Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42 J cells into glucagon- and insulin-producing cells. Diabetes. 1999;48:2358–2366
  28. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144:5149–5158
  29. Drucker DJ. The biology of incretin hormones. Cell Metabolism. 2006;3:153–165
  30. Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78–107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123:2009–2013
  31. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. The Journal of Clinical Endocrinology Metabolism. 2001;86:3717–3723
  32. Shah P, Vella A, Basu A, et al. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. The Journal of Clinical Endocrinology Metabolism. 2000;85:4053–4059
  33. Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7–36) amide in type I diabetic patients. Diabetes Care. 1996;19:580–586
  34. de Heer J, Hoy M, Holst JJ. GLP-1, but not GIP, inhibits glucagon secretion via somatostatin in the perfused rat pancreas. [Abstract] Diabetologia. 2005;48(Suppl. 1):
  35. Fehmann HC, Goke R, Goke B. Cell and molecular biology of the incretin hormones glucagon- like peptide-I and glucose-dependent insulin releasing polypeptide. Endocrine Reviews. 1995;16:390–410
  36. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes. 1997;46:785–791
  37. Moens K, Heimberg H, Flamez D, et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes. 1996;45:257–261
  38. Tornehave D, Kristensen P, Romer J, et al. Expression of the GLP-1 receptor in mouse, rat, and human pancreas. The Journal of Histochemistry and Cytochemistry. 2008;56:841–851
  39. Ding WG, Renstrom E, Rorsman P, et al. Glucagon-like peptide I and glucose-dependent insulinotropic polypeptide stimulate Ca2+-induced secretion in rat alpha-cells by a protein kinase A-mediated mechanism. Diabetes. 1997;46:792–800
  40. Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. The Journal of Clinical Endocrinology Metabolism. 2002;87:1239–1246
  41. Wettergren A, Schjoldager B, Mortensen PE, et al. Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man. Digestive Diseases and Sciences. 1993;38:665–673
  42. Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. American Journal of Physiology. 1997;273:E981–E988
  43. Layer P, Holst JJ, Grandt D, et al. Ileal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Digestive Diseases and Sciences. 1995;40:1074–1082
  44. Schjoldager BT, Mortensen PE, Christiansen J, et al. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Digestive Diseases and Sciences. 1989;34:703–708
  45. Groger G, Unger A, Holst JJ, et al. Ileal carbohydrates inhibit cholinergically stimulated exocrine pancreatic secretion in humans. International Journal of Pancreatology. 1997;22:23–29
  46. Wettergren A, Maina P, Boesby S, et al. Glucagon-like peptide-1 7–36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Scandinavian Journal of Gastroenterology. 1997;32:552–555
  47. Read N, French S, Cunningham K. The role of the gut in regulation food intake in man. Nutrition Reviews. 1994;52:1–10
  48. Holst JJ. Enteroglucagon. Annual Review of Physiology. 1997;59:257–271
  49. Layer P. Intestinal regulation of pancreatic enzyme secretion: stimulatory and inhibitory mechanisms, Intestinale Regulation der Pankreasenzymsekretion: Stimulatorische und inhibitorische Mechanismen Z Gastroenterology. 1992;30:495–497
  50. Wettergren A, Petersen H, Orskov C, et al. Glucagon-like peptide-1 7–36 amide and peptide YY from the L- cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scandinavian Journal of Gastroenterology. 1994;29:501–505
  51. Wettergren A, Wojdemann M, Meisner S, et al. The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7–36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut. 1997;40:597–601
  52. Schirra J, Nicolaus M, Roggel R, et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut. 2006;55:243–251
  53. Vilsboll T, Agerso H, Krarup T, et al. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. The Journal of Clinical Endocrinology Metabolism. 2003;88:220–224
  54. Hansen L, Deacon CF, Orskov C, et al. Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. [In Process Citation] Endocrinology. 1999;140:5356–5363
  55. Holst JJ, Deacon CF. Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia. 2005;48:612–615
  56. Nishizawa M, Nakabayashi H, Uchida K, et al. The hepatic vagal nerve is receptive to incretin hormone glucagon-like peptide-1, but not to glucose-dependent insulinotropic polypeptide, in the portal vein. Journal of the Autonomic Nervous System. 1996;61:149–154
  57. Nakabayashi H, Nishizawa M, Nakagawa A, et al. Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. American Journal of Physiology. 1996;271:E808–E813
  58. Karlsson S, Scheurink AJ, Steffens AB, et al. Involvement of capsaicin-sensitive nerves in regulation of insulin secretion and glucose tolerance in conscious mice. American Journal of Physiology. 1994;267:R1071–R1077
  59. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. The Journal of Clinical Endocrinology Metabolism. 2003;88:2706–2713
  60. Holst JJ. Glucagon-like Peptide 1(GLP-1): an intestinal hormone signalling nutritional abundance, with an unusual therapeutic potential. Trends in Endocrinology and Metabolism. 1999;10:229–234
  61. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent- mediated central mechanisms. American Journal of Physiology. 1997;273:G920–G927
  62. Wettergren A, Wojdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. American Journal of Physiology. 1998;275:G984–G992
  63. Holst JJ, Rasmussen TN, Harling H, et al. Effect of intestinal inhibitory peptides on vagally induced secretion from isolated perfused porcine pancreas. Pancreas. 1993;8:80–87
  64. Burcelin R, Da Costa A, Drucker D, et al. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes. 2001;50:1720–1728
  65. Ionut V, Liberty IF, Hucking K, et al. Exogenously imposed postprandial-like rises in systemic glucose and GLP-1 do not produce an incretin effect, suggesting an indirect mechanism of GLP-1 action. American Journal of Physiology Endocrinology and Metabolism. 2006;291:E779–E785
  66. Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987;2:1300–1304
  67. Hvidberg A, Nielsen MT, Hilsted J, et al. Effect of glucagon-like peptide-1 (proglucagon 78–107amide) on hepatic glucose production in healthy man. Metabolismo. 1994;43:104–108
  68. Jin SL, Han VK, Simmons JG, et al. Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. The Journal of Comparative Neurology. 1988;271:519–532
  69. Schick RR, vorm Walde T, Zimmermann JP, et al. Glucagon-like peptide 1-a novel brain peptide involved in feeding regulation. In:  Ditschuneit H,  Gries FA,  Hauner H, et al. editor. Obesity in Europe 1993. John Libbey & Co.Ltd; 1994;p. 363–367
  70. Tang-Christensen M, Larsen PJ, Goke R, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. American Journal of Physiology. 1996;271:R848–R856
  71. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. [see comments] Nature. 1996;379:69–72
  72. Tang-Christensen M, Vrang N, Larsen PJ. Glucagon-like peptide 1(7–36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes. 1998;47:530–537
  73. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology. 2001;142:4244–4250
  74. Tang-Christensen M, Larsen PJ, Thulesen J, et al. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. [In Process Citation] Natural Medicines. 2000;6:802–807
  75. Flint A, Raben A, Astrup A, et al. Glucagon-like Peptide 1 promotes satiety and suppresses energy intake in humans. The Journal of Clinical Investigation. 1998;101:515–520
  76. Verdich C, Flint A, Gutzwiller JP, et al. A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. The Journal of Clinical Endocrinology Metabolism. 2001;86:4382–4389
  77. Naslund E, Barkeling B, King N, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. International Journal of Obesity Related Metabolic Disorders. 1999;23:304–311
  78. Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. American Journal of Physiology. 1999;276:R1541–R1544
  79. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet. 2002;359:824–830
  80. Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372:1240–1250
  81. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481
  82. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion. 2008;24:275–286
  83. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259–267
  84. Orskov C, Poulsen SS, Moller M, et al. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45:832–835
  85. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon- like peptide 1 (7–36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741–744
  86. D'Alessio DA, Kahn SE, Leusner CR, et al. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin- independent glucose disposal. The Journal of Clinical Investigation. 1994;93:2263–2266
  87. Toft-Nielsen M, Madsbad S, Holst JJ. The effect of glucagon-like peptide I (GLP-I) on glucose elimination in healthy subjects depends on the pancreatic glucoregulatory hormones. Diabetes. 1996;45:552–556
  88. Orskov L, Holst JJ, Moller J, et al. GLP-1 does not acutely affect insulin sensitivity in healthy man. Diabetologia. 1996;39:1227–1232
  89. Vella A, Shah P, Reed AS, et al. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Diabetologia. 2002;45:1410–1415
  90. Ahren B, Larsson H, Holst JJ. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology Metabolism. 1997;82:473–478
  91. Vella A, Shah P, Basu R, et al. Effect of glucagon-like peptide 1(7–36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000;49:611–617
  92. Meneilly GS, Greig N, Tildesley H, et al. Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. Diabetes Care. 2003;26:2835–2841
  93. Nishizawa M, Moore MC, Shiota M, et al. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. American Journal of Physiology Endocrinology and Metabolism. 2003;284:E1027–E1036
  94. Dardevet D, Moore MC, Neal D, et al. Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. American Journal of Physiology Endocrinology and Metabolism. 2004;287:E75–E81
  95. Ionut V, Hucking K, Liberty IF, et al. Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia. 2005;48:967–975

PII: S1521-690X(09)00030-X

doi: 10.1016/j.beem.2009.03.011

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 23, Issue 4 , Pages 453-462 , August 2009

Article Tools